The possible beneficial effect of aprotinin, a broad protease inhibitor, on the incidence and outcome of ARDS was examined in two complementary studies. In the first study, the effect of aprotinin was assessed in 147 patients admitted with multiple trauma or shock. In the 57 patients who developed ARDS, mortality was significantly less in those who had previously received aprotinin (8/20, 40%) than in those who had not (26/37, 70%). Although both treatment groups were well matched, this was a retrospective study and a second prospective, randomised, controlled study was therefore carried out. In 78 patients at risk of ARDS, there was no significant difference between treated and control patients in the incidence, duration or severity of ARDS, or in mortality or other major complications. It is concluded that aprotinin is not effective in improving any aspect of ARDS or its outcome in seriously ill patients.
our policy for several years to give aprotinin for 48 hours to patients admitted soon after major trauma or with shock, and thus considered at risk of developing ARDS. The present study is in two parts. First, a retrospective evaluation was made of the policy of giving aprotinin prophylactically to high-risk patients. Since the results of this survey suggested that aprotinin might be of benefit, a second study was undertaken in the form of a randomised, controlled study of prophylactic aprotinin in high-risk patients.
PATIENTS AND METHODS

First study Patients
Patients studied were those admitted during a twelve-month period to a general Intensive Care Unit of a major teaching hospital following multiple trauma or with hypovolaemic or septic shock. The subsequent development of ARDS, other major complications, therapeutic measures and outcome were recorded. The diagnostic criteria for ARDS are described below.
Treatment
Aprotinin was given only to those patients admitted to the Intensive Care Unit within 24 hours of trauma or shock. Treatment details are described below.
Second study Patients
Patients were studied during a subsequent twelve-month period in the same general Intensive Care Unit.
The criteria for inclusion were: 1. Major trauma which included two or more of the following -head injury, chest injury, cardiac injury, abdominal injury, pelvic fracture, long leg bone fracture, or extended soft tissue injury not accounted for in the preceding injuries. 2. Major haemorrhage from any site resulting in shock or requiring massive transfusion. Major haemorrhage was defined as requiring transfusion of six units or more of blood within 24 hours in patients who were shocked, or ten units or more of blood within 24 hours (massive transfusion) in patients who were not shocked. If these criteria were not subsquently met after initial trial entry, the patient became ineligible to continue. (In the event, no patient was excluded for this reason). Shock was defined as systolic blood pressure less than 100 mmHg for 30 minutes or more with clinical evidence of circulatory insufficiency. 3. Major thoracic or abdominal surgery which was prolonged or complicated and required postoperative intensive care. 4. Major sepsis consisting of widespread proven bacterial infection in the thoracic or abdominal cavities or soft tissues, or proven septicaemic shock from any source. 5. Non-cardiogenic shock from any cause. 6. Availability to enter the trial in less than twelve hours after the onset of any of the risk factors listed in criteria 1-5 above. The diagnostic criteria for ARDS are described below.
Methods
Eligible patients were randomised to treatment (aprotinin) or control groups. Treatment details are described below. A placebo control was not possible because coded ampoules of aprotinin and placebo of similar appearance were not available. The conduct of the trial was single-blind. The management of the two groups of patients was otherwise the same.
Recording was made of the primary insult, viz. trauma, haemorrhage, surgery, sepsis or shock, together with the time from its onset to the commencement of treatment. The presence of direct pulmonary injury and of pre-existing lung disease was separately recorded. Other pre-existing diseases present at the time of the primary insult were also recorded, including cardiac, vascular, hepatic, renal, endocrine and autoimmune disease. Specific note was also made of the early use of corticosteroids, the severity of shock using the minimum systolic blood pressure and the time during which the systolic blood pressure was less than 100 mmHg, and the presence of metabolic acidosis as defined by arterial pH < 7.30 with arterial Pe02 within the range 36-44 mmHg. Daily recordings were made for the duration of the patient's admission of inspired oxygen concentration (F 102), arterial blood gas analysis, ventilatory variables, haematological variables, clotting profile, renal function and major therapeutic modalities.
The following derived respiratory variables were calculated: 1. Alveolar-arterial oxygen tension difference (A-a diff. P0 2 ), 2. P a 0 2 /F l 0 2 ratio, and 3. Dynamic compliance (C dyn ), defined as tidal volume divided by peak inspiratory airway pressure.
For each derived respiratory variable and for positive end-expiratory pressure (PEEP), both the mean and the worst of the daily values were recorded.
Both studies Diagnosis of ARDS
The diagnosis of ARDS was by usually accepted criteria. I -9 These included the presence of all of the following features: 1. Acute respiratory failure as shown by P a o 2 <60 mmHg despite an FI02~0.40, 2. Chest X-ray showing bilateral pulmonary infiltrate, and 3. Exclusion of cardiogenic pulmonary oedema or fluid overload, clinically by trial of diuresis in patients with positive fluid balance, age over 50 years or a history of ischaemic heart disease (patients with heart disease that was symptomatic or required treatment were excluded), and physiologically by central venous pressure measurement < 15 cm H 2 0 referred to mid-axillary line. Pulmonary artery catheterisation was neither possible nor deemed necessary in all patients, so that pulmonary artery wedge pressure measurements were not a requirement for diagnosis.
Aprotinin treatment
Aprotinin (Trasylol, Bayer) was administered intravenously in a loading dose of 500,000 U followed by 100,000 U two-hourly for 48 hours, each dose being given over 10 minutes.
Statistical analysis
Statistical analysis of variables which were either present or absent were made using the Chi square test. Continuous numerical variables were compared using the unpaired t test.
RESULTS
First study
Of the 147 admissions which followed trauma or shock, 93 received aprotinin and 54 did not. Fifty-seven of the 147 patients developed ARDS, an incidence of 8070 of all admissions and of 39% after trauma or shock. The incidence of ARDS was significantly less in those who had been given aprotinin (20/93, 22%) than in those who had not (37/54, 69%) (P < 0.001).
The outcome of patients with ARDS is shown on Table 1 . The mortality of all patients with ARDS was 60% (34/57). For those with ARDS after trauma, it was 29% (4/29) and for those with ARDS without trauma, it was 70% (30/43). Mortality was significantly less in patients with ARDS who had received aprotinin (8120, 40%) than in those who had not (26/37, 70%) (P < 0.05). This treatment difference was most marked in patients with trauma and ARDS (P < 0.05). The same trend with treatment was seen in patients without trauma but the difference was not significant.
In patients with ARDS, comparison of those who had received aprotinin with those who had not ( Table 2 ) showed no significant differences in sex, age, diagnostic category (nature of trauma, surgery or resuscitation), presence of shock, septicaemia, renal failure, liver failure, coma, hypoalbuminaemia, hyponatraemia, metabolic acidosis, disseminated intravascular coagulation (DIC), or use of PEEP, central venous pressure (CVP) monitoring, blood products, antibiotics, steroids or parenteral nutrition (TPN). Maximum inspired oxygen concentration (F102) over 60% was significantly more common in those who had been given aprotinin than in those who had not (80% and 32% of patients, respectively; P<O.OOI). These problems and therapeutic requirements were those which had previously been found to be relevant to the outcome after ARDS.
Second study
Of the 78 patients who entered into the study, there were 36 treated patients and 42 control patients. The details of the entry criteria and primary insult of the two groups are shown in Table 3 and comparison of the clinical details on entry in shown in Table 4 . As shown in these tables, treated patients tended to have had less surgery, to be younger, and to have had a greater incidence of shock than control patients.
Comparison of the outcome variables between the treatment and control groups is shown in Table 5 . There were no significant differences in the incidence of ARDS nor in mortality. There was also no significant difference in the duration or severity of ARDS as reflected in the variables of lung function or ventilatory support (IPPV), nor were there any significant differences in haematological variables or incidence of renal failure.
Patients in the chief entry categories of trauma, haemorrhage and sepsis (from Table 3 ) were separately analysed for the major outcome variables, as shown in Table 6 . Within each of these categories, there were no significant differences between the treated and control groups, except that the duration of ventilatory support was longer in treated patients in the major haemorrhage subgroup.
Of the 78 high-risk patients entered into the study, 25 (32070) developed ARDS. Within this group, comparisons of entry variables and outcome variables between treated and control patients are shown in Table 7 . As in the previous comparison for all patients (Tables 3  and 4 ), treated and control patients were comparable on entry, except that treated patients had had less surgery were younger and had a greater incidence of shoc,k than control patients. There was no significant differences in outcome variables between the two groups.
DISCUSSION
Although ARDS arises following a diversity of primary insults, pulmonary capillary damage with increased permeability is recognised as the common factor in its developmenL 8 ,9, individual contribution of these separate mechanisms to the development of ARDS is unclear. However, each mechanism gives a role either directly or indirectly to neutrophil protease activity, thus leading to increased pulmonary capillary permeability. 34, 37, 38 Although such mechanisms linking unopposed protease activity to ARDS remain speculative,2° the clinical assessment of the potential therapeutic value of anti-protease agents would seem logical. Aprotinin (Trasylol), a basic polypeptide derived from bovine lungs, is a broad protease inhibitor, with special affinity for kallikrein, plasmin, trypsin, and leukocyte lysosomal proteases. 12 ,39,40 Although it was first isolated in 1926 and introduced into clinical medicine nearly 30 years ago,40 aprotinin has yet to gain a clear therapeutic role despite theoretical and experimental evidence indicating potential application in a variety of clinical situations. 12 ,13.39 Among these, its potential value in shock and the possibility that it might prevent shock lung, or ARDS, have been advocated but never fully evaluated. 13 -19 ,37 However, beneficial effects of aprotinin have been reported in animal models of posttraumatic fat embolism 41 -43 and ARDS from gram-negative endotoxin. 44 Clinical studies of aprotinin given prophylactically to patients at risk of post-traumatic respiratory insufficiency have shown smaller reductions in platelet count, improved pulmonary gas transfer and decreased mortality in treated patients. 19 .45,46 The results of our first study tended to confirm the suggestion that aprotinin might prevent ARDS in high-risk patients. Thus, the incidence of ARDS in the 147 high-risk patients in this study was significantly less in those who had received aprotinin (22070) than those who had not (69070), a finding in keeping with previous claims. In addition, an unexpected and hitherto unreported finding was that in the 57 patients who developed ARDS, those whom had been given aprotinin subsequently fared significantly better than those who had not, with a mortality of 40070 compared to 70070. This difference was especially striking in the subgroup of patients with ARDS after multiple trauma in whom mortality was 0070 in those who had been given aprotinin and 50070 in those who had not.
Anaesthesia and Intensive Care, Vol. 14. No. 4, November, 1986 Comparison of patients who were and who were not given aprotinin failed to show any significant differences in sex, age, diagnostic categories, associated problems or therapeutic measures, except that inspired oxygen requirements were higher in those who had been given aprotinin. Thus, the two groups of patients appeared comparable on all definable grounds previously correlated with survival, which seemed to exclude the possibility that patients not given aprotinin were in some way a more seriously ill group to begin with. However, the first study was a restrospective survey and different selection criteria for patients who were given aprotinin compared with those who were not could have contributed to the result, even though subgroup comparisons showed that patients with ARDS who had or had not received aprotinin appeared to be well matched.
The second study was thus designed as a prospective, randomised, controlled trial. In this study, no significant difference in the incidence or severity of ARDS or its outcome could be demonstrated between those high-risk patients who were given aprotinin prophylactically and those who were not. This lack of statistically significant difference, or indeed of any suggestive trend, was apparent not only in the overall group of patients but also in each of the separately analysed subgroups of patients.
The reason for the lack of efficacy of aprotinin in the second study is uncertain. The mean delay of five hours before treatment was commenced and the dose of aprotinin were comparable with those of previous studies. 19.43.45.46 It would thus appear that the pathogenesis of ARDS is either not significantly contributed to by increased protease activity or else is multifactorial. We conclude that the favourable results of the first study were the result of patient selection and that the results of the second study indicated that prophylactic aprotinin was ineffective in improving any aspect of ARDS or its outcome in seriously ill patients.
